AC
MLTX icon

Aaron Cowen’s MoonLake Immunotherapeutics MLTX Stock Holding History

Aaron Cowen’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35,344
Closed -$361K – 129
2021
Q1 		$361K Sell
35,344
-164,656
-82% -$1.82M 0.01% 102
2020
Q4 		$2.27M Buy
+200,000
New +$2.12M 0.03% 86

Other funds holding MLTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Aaron Cowen's MLTX Position: Q2 2021 in Review

Aaron Cowen sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2021, closing a stake of 35,344 shares — an estimated $361K sold.

Aaron Cowen first reported a position in MLTX in Q4 2020 and held it in 2 quarters. The position peaked at $2.27M in Q4 2020. 46 funds tracked by Wall St. Rank hold MLTX as of Q2 2021.

  • Aaron Cowen reported no remaining MoonLake Immunotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Aaron Cowen sold 35,344 MoonLake Immunotherapeutics shares in Q2 2021, an estimated $361K.
  • Aaron Cowen first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 2 quarters.
  • Aaron Cowen's MoonLake Immunotherapeutics position peaked at $2.27M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2021.

Based on Suvretta Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.